Dermatomyositis Causes and Symptoms – Overview

1
Dermatomyositis - Pipeline Review H1 2016
Telephone [phone]Mail at
sales_at_researchbeam.com
(Type, Mode of action, Crop Type and Geography) -
Size, Share, Global Trends, Company Profiles,
Demand, Insights, Analysis, Research, Report,
Opportunities, Segmentation and Forecast, 2013 -
2020
Published on Oct 2014
2


Report Overview

• Dermatomyositis - Pipeline Review, H1 2016,
  provides an overview of the Dermatomyositis
  pipeline landscape.
• The report provides comprehensive information on
  the therapeutics under development for
  Dermatomyositis, complete with analysis by stage
  of development, drug target, mechanism of action
  (MoA), route of administration (RoA) and molecule
  type. The report also covers the descriptive
  pharmacological action of the therapeutics, its
  complete research and development history and
  latest news and press releases. Additionally, the
  report provides an overview of key players
  involved in therapeutic development for
  Dermatomyositis and features dormant and
  discontinued projects.
• This report features investigational drugs from
  across globe covering over 20 therapy areas and
  nearly 3,000 indications. The report is built
  using data and information sourced from
  proprietary databases, company/university
  websites, clinical trial registries, conferences,
  SEC filings, investor presentations and featured
  press releases from company/university sites and
  industry-specific third party sources. Drug
  profiles featured in the report undergoes
  periodic review following a stringent set of
  processes to ensure that all the profiles are
  updated with the latest set of information.
  Additionally, various dynamic tracking processes
  ensure that the most recent developments are
  captured on a real time basis.
• The report helps in identifying and tracking
  emerging players in the market and their
  portfolios, enhances decision making capabilities
  and helps to create effective counter strategies
  to gain competitive advantage.
• Strategic Focus Report http//www.researchbeam.co
  m/dermatomyositis-pipeline-review-h1-2016-market

3


Report Overview

• Scope
• - The report provides a snapshot of the global
  therapeutic landscape of Dermatomyositis
• - The report reviews pipeline therapeutics for
  Dermatomyositis by companies and
  universities/research institutes based on
  information derived from company and
  industry-specific sources
• - The report covers pipeline products based on
  various stages of development ranging from
  pre-registration till discovery and undisclosed
  stages
• - The report features descriptive drug profiles
  for the pipeline products which includes, product
  description, descriptive MoA, RD brief,
  licensing and collaboration details other
  developmental activities
• Reasons to buy
• - Gain strategically significant competitor
  information, analysis, and insights to formulate
  effective RD strategies
• - Identify emerging players with potentially
  strong product portfolio and create effective
  counter-strategies to gain competitive advantage
• - Identify and understand important and diverse
  types of therapeutics under development for
  Dermatomyositis
• - Develop strategic initiatives by understanding
  the focus areas of leading companies
• - Plan mergers and acquisitions effectively by
  identifying key players and its most promising
  pipeline therapeutics

4


Table of Contents
Table of Contents 2 List of Tables 4 List of
Figures 4 Introduction 5 Global Markets Direct
Report Coverage 5 Dermatomyositis Overview
6 Therapeutics Development 7 Pipeline Products
for Dermatomyositis - Overview 7 Dermatomyositis
- Therapeutics under Development by Companies
8 Dermatomyositis - Pipeline Products Glance
9 Clinical Stage Products 9 Early Stage Products
10 Dermatomyositis - Products under Development
by Companies 11 Dermatomyositis - Companies
Involved in Therapeutics Development 12 F.
Hoffmann-La Roche Ltd. 12 Hope Pharmaceuticals,
Inc. 13 Idera Pharmaceuticals, Inc. 14 MedImmune,
LLC 15 Neovacs SA 16 Novartis AG
17 Dermatomyositis - Therapeutics Assessment
18 Assessment by Monotherapy Products
18 Assessment by Target 19
5


Report Ordering
Report Name Dermatomyositis -
Pipeline Review H1 2016
Product Price
User Price
Single User US 1700
Site User US 4000
Global User US 6000
To View Sample or Purchase Report
6



Contact Us
FOR MORE DETAILS
Visit us at
http//www.researchbeam.com/dermatomyositis-pipeli
ne-review-h1-2016-market
Stay With Us At
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone] DIRECT 1 (503)
894-6022E-MAIL sales_at_researchbeam.com